As manufacturers invest in clinical development of rare disease therapies, payers are examining disease prevalence estimates and determining reimbursements. In this article published in Life Science Leader, Cécile Matthews and Bhavesh Patel discuss factors payers are considering for such reimbursements. The authors recently conducted an analysis of 15 rare and ultra-rare disease therapies recently approved in France, Germany, Italy, Spain, the UK, and Japan to better understand the factors payers are now considering for reimbursement of rare disease drugs.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...